Hospital Alemán

Futó vizsgálatok

• Még nem toboroz

  Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients

  NCT07771400· Forrás

• Toboroz

  A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07589634· 2. fázis· Forrás

• Toboroz

  A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  NCT07634471· 2/3. fázis· Forrás

• Toboroz

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· 3. fázis· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· 3. fázis· Forrás

• Toboroz

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· 2/3. fázis· Forrás

• Toboroz

  A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07043400· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· 2. fázis· Forrás

• Toboroz

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· 3. fázis· Forrás

• Toboroz

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· 3. fázis· Forrás

• Toboroz

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· 3. fázis· Forrás

• Toboroz

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  NCT06717347· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· 3. fázis· Forrás

• Fut, nem toboroz

  A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

  NCT05933577· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· 3. fázis· Forrás

• Meghívásos bevonás

  Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

  NCT05645536· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

  NCT05471843· 1/2. fázis· Forrás

• Toboroz

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· 2. fázis· Forrás

• Fut, nem toboroz

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  NCT05100862· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05083169· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  NCT04923893· 3. fázis· Forrás

• Fut, nem toboroz

  Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

  NCT04906395· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

  NCT04576156· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

  NCT04634877· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

  NCT04526665· 3. fázis· Forrás

• Fut, nem toboroz

  Procedure for Duodenum to Ileal Diversion to Treat Type 2 Diabetes

  NCT03130244· Forrás

• Fut, nem toboroz

  A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Petefészekrák3 toboroz
• Gyomor- és nyelőcsőrák2 toboroz
• Hólyagrák2 toboroz
• Krónikus limfoid leukémia (CLL)2 toboroz
• Mielóma multiplex2 toboroz
• Áttétes emlőrák1 toboroz
• Crohn-betegség1 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Fej-nyaki daganatok1 toboroz
• Follikuláris limfóma1 toboroz
• Hasnyálmirigyrák1 toboroz
• Köpenysejtes limfóma1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhnyakrák1 toboroz
• Méhtestrák1 toboroz
• Melanóma1 toboroz
• Tripla negatív emlőrák1 toboroz
• Tüdőrák1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Leállították

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· 1/2. fázis· Forrás

• Lezárult

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· 3. fázis· Forrás

• Leállították

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· 3. fázis· Forrás

• Lezárult

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· 2. fázis· Forrás

• Lezárult

  Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

  NCT03976375· 3. fázis· Forrás

• Lezárult

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· 3. fázis· Forrás

• Lezárult

  Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· 3. fázis· Forrás

• Lezárult

  Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

  NCT03884101· 3. fázis· Forrás

• Lezárult

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319· 3. fázis· Forrás

• Lezárult

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· 2. fázis· Forrás

• Lezárult

  Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

  NCT03635567· 3. fázis· Forrás

• Lezárult

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· 3. fázis· Forrás

• Lezárult

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· 3. fázis· Forrás

• Lezárult

  A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

  NCT02576431· 2. fázis· Forrás

• Lezárult

  Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

  NCT02303821· 1. fázis· Forrás

Vizsgálati helyszínek

• Aleman Hospital1 vizsgálat
• Hospital Alemán16 vizsgálat
• Hospital Aleman de Buenos Aires2 vizsgálat
• Hospital Aleman (Site 0101)1 vizsgálat
• Hospital Aleman (Site 0210)1 vizsgálat
• Hospital Aleman (Site 0301)1 vizsgálat
• Hospital Aleman (Site 0368)1 vizsgálat
• Hospital Aleman (Site 0806)1 vizsgálat
• Hospital Aleman (Site 1001)1 vizsgálat
• Hospital Aleman (Site 1004)1 vizsgálat
• Hospital Aleman (Site 1005)1 vizsgálat
• Hospital Aleman (Site 2000)1 vizsgálat
• Hospital Aleman (Site 2100)1 vizsgálat
• Hospital Aleman (Site 2200)1 vizsgálat
• Hospital Aleman (Site 2600)1 vizsgálat
• Hospital Alemán11 vizsgálat
• Hospital Aleman2 vizsgálat
• Hospital Aleman2 vizsgálat
• Hospital Aleman1 vizsgálat
• Hospital Alemán1 vizsgálat

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Neuromyelitis optica (NMOSD)7 munka · 0 vizsgálat